Edwards Lifesciences Corporation
Edwards Lifesciences is globally recognized as the leader and pioneer in the structural heart devices market, particularly renowned for its groundbreaking work in transcatheter heart valve technology. Founded in 1958, the company has consistently focused on patient-focused innovation to treat advanced cardiovascular disease. Edwards Lifesciences revolutionized the treatment of aortic stenosis with its flagship SAPIEN transcatheter aortic valve replacement (TAVR) systems, such as the SAPIEN 3 Ultra, which holds a majority share of the global TAVR market. Beyond TAVR, the company provides comprehensive surgical valve technologies, including the trusted Carpentier-Edwards annuloplasty rings for mitral valve repair and advanced RESILIA tissue valves. Edwards maintains its leadership by heavily investing in R&D, clinical evidence, and collaborative partnerships with cardiac centers worldwide, ensuring its devices continue to set the industry standard for durability and patient safety in complex structural heart procedures, including emerging transcatheter mitral and tricuspid technologies.
Latest Market Research Report on Structural Heart Devices Download PDF Brochure Now
Medtronic plc
Medtronic is a premier global healthcare technology company headquartered in Ireland, known for its extensive range of medical devices and solutions across more than 150 countries. As a formidable leader in the structural heart market, Medtronic focuses on developing innovative, durable solutions for valvular heart diseases. The company’s core offering is the CoreValve/Evolut transcatheter aortic valve system, including the Evolut FX+ TAVR system, designed for minimally invasive replacement procedures and known for its supra-annular design that aims to optimize hemodynamic performance. Medtronic provides comprehensive solutions spanning both mechanical and tissue heart valves, and actively incorporates integrated digital solutions and remote monitoring technologies into its platforms. By leveraging its vast global reach and commitment to continuous innovation, Medtronic helps shape next-generation care models in cardiology, aiming to improve long-term patient outcomes through highly effective and durable cardiac prosthetic devices.
Abbott Laboratories
Abbott Laboratories is a U.S.-based global healthcare giant with a legacy of over a century of innovation in cardiovascular health and advanced medical devices. In the structural heart arena, Abbott is distinguished by its market-leading focus on minimally invasive repair and closure technologies for mitral and tricuspid valve disease. Its flagship product, the MitraClip, is the world’s most implanted device for mitral valve repair, designed to treat mitral regurgitation without open-heart surgery. Building on this success, Abbott also pioneered the TriClip system for tricuspid regurgitation. Furthermore, the company offers the Navitor Transcatheter Aortic Valve Implantation (TAVI) system and a range of structural intervention devices like the Amplatzer occluders for septal defects (PFO, ASD). By prioritizing less-invasive procedures and innovative device designs, Abbott remains a dominant force, significantly enhancing patient access to cutting-edge cardiovascular interventions.
Boston Scientific Corporation
Boston Scientific Corporation is a leading U.S.-based medical device manufacturer known for its comprehensive portfolio in interventional cardiology, with a major focus on the structural heart market. The company excels in providing devices that enhance procedural efficiency and safety. Boston Scientific is the global market leader in Left Atrial Appendage Closure (LAAC) technology, prominently featuring the WATCHMAN FLX™ and WATCHMAN FLX Pro devices, which are critical for stroke risk reduction in nonvalvular atrial fibrillation patients. Additionally, the company offers the ACURATE neo2 TAVR system for aortic valve replacement and the SENTINEL™ Cerebral Protection System, designed to reduce stroke risk during TAVR procedures. Through continuous investment in minimally invasive solutions and advanced closure devices, Boston Scientific maintains its position at the vanguard of the structural heart landscape, striving to optimize clinical outcomes globally.
LivaNova PLC
LivaNova PLC is a global medical technology company headquartered in the UK, specializing in therapeutic solutions for cardiac surgery and neuromodulation. In the structural heart devices market, LivaNova focuses on specialized expertise in heart valve replacement and tissue repair devices, offering solutions for a broad range of surgical and transcatheter procedures. The company is particularly recognized for its mechanical heart valves and sutureless aortic valves, which are designed to simplify surgical complexity and improve patient recovery times. LivaNova also actively invests in devices targeting pediatric heart conditions. By focusing on high-quality manufacturing, innovative design, and clinical reliability, LivaNova serves as a key player in the traditional cardiac surgery space while expanding its offerings in less-invasive structural heart interventions, providing physicians with reliable tools for complex cardiovascular repairs.
Artivion, Inc.
Artivion, Inc., formerly known as CryoLife, is a U.S.-based medical device company that offers differentiated surgical solutions for complex structural heart diseases. Artivion specializes in the provision of cryopreserved cardiovascular and orthopedic tissues, which are critical components in many complex cardiac reconstruction procedures. In the structural heart market, the company is known for its offerings in aortic valve replacement and repair technologies, including specialized conduits and grafts. Artivion’s core strategy emphasizes clinical excellence through a combination of high-quality tissue products and innovative surgical devices. By maintaining a strong research focus and executing targeted expansions, Artivion provides specialized, patient-centric products that support surgeons in addressing intricate structural heart conditions where traditional off-the-shelf devices may not be suitable, underscoring its commitment to complex cardiac care.
BIOTRONIK SE & Co. KG
BIOTRONIK SE & Co. KG is a German-based medical technology company with a long history as a pioneer in cardiac rhythm management, and it is also a significant contributor to the structural heart market. The company leverages its deep expertise in implantable technology to develop advanced structural heart implants and interventional devices. BIOTRONIK’s focus is on integrated solutions, combining robust device reliability with sophisticated digital health and home-monitoring capabilities. This integration ensures seamless device delivery and optimized long-term outcomes for patients. Its commitment to precision engineering and proactive regulatory compliance, particularly in the EU, allows BIOTRONIK to deliver highly reliable and physician-friendly cardiovascular solutions, enhancing care quality across various structural heart procedures.
JenaValve Technology, Inc.
JenaValve Technology, Inc., with roots in Germany, is an agile company dedicated to developing innovative transcatheter solutions for severe valvular heart disease. The company specializes in the development of TAVR systems for patients suffering from both aortic stenosis and the particularly complex condition of aortic regurgitation (AR). JenaValve’s technology is distinct due to its unique fixation mechanism and transapical or transfemoral delivery options, allowing for precise, patient-specific device adaptations in challenging anatomies. Their focus on overcoming limitations of current TAVR devices, such as treating severe AR, makes them a crucial innovator in the structural heart space, attracting partnerships and potential acquisitions from major industry players aiming to strengthen their advanced structural heart portfolios.
MicroPort Scientific
MicroPort Scientific Corporation is a high-end medical device company with a strong international presence, focusing on cardiovascular, orthopedic, and neurovascular technologies. In the structural heart sector, MicroPort is a key innovator, particularly within the Asian and emerging global markets. The company actively drives the adoption of advanced implantable devices, including transcatheter heart valves, through significant investment in R&D and robust manufacturing capabilities. MicroPort offers solutions like TAVR and other cardiac prosthetic devices, aiming to provide high-quality, cost-effective alternatives to address the growing cardiovascular needs globally. By expanding its suite of implantables and focusing on advanced manufacturing processes, MicroPort accelerates market penetration and access to innovative structural heart interventions across key international regions.
Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve patient health and enhance clinical safety across several medical specialties, including interventional cardiology. Within the structural heart domain, Teleflex focuses on critical procedural support devices necessary for safe and efficient transcatheter interventions. Key products include the MANTA Vascular Closure Device, which significantly reduces time to hemostasis after large-bore femoral access procedures common in TAVR and TMVR. They also offer the Wattson Temporary Pacing Guidewire, used for effective pacing during procedures like TAVR and balloon aortic valvuloplasty. Teleflex’s commitment lies in providing specialized tools that address the technical challenges faced by interventional cardiologists, thus supporting the broader adoption and successful execution of complex structural heart procedures.
Latest Market Research Report on Structural Heart Devices Download PDF Brochure Now